Drugs / 18F-Sodium Fluoride (NaF)
18F-Sodium Fluoride (NaF)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01930812 | Jul 2014 → Mar 2017 | metastatic carcinoma in the bone | British Columbia Cancer Agency | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Sodium Fluoride (NaF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01930812 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic imaging test that is considered investigational” NCT01930812 ↗ |
| Route | Intravenous | “is intravenously administered” NCT01930812 ↗ |